• 1
    Antiepileptic drugs pharmacology and therapeutics. 2nd ed. London: Springer, 1999.
  • 2
    Clinical epilepsy. 1st ed. Edinburgh: Churchill Livingstone, 1995.
  • 3
    Heaney DC, Shorvon SD, Sander JWAS. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1994;39(suppl 3):S1925.
  • 4
    Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
  • 5
    Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programs. Oxford: Oxford University Press, 1997.
  • 6
    Diener A, O'Brien B, Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Econ 1998;7:31326.DOI: 10.1002/(sici)1099-1050(199806)7:4<313::aid-hec350>;2-2
  • 7
    Sander JWAS. New drugs for epilepsy. Curr Opin Neurol 1998;11:1418.DOI: 10.1097/00019052-199804000-00011
  • 8
    Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:45160.
  • 9
    Baker GA, Camfield C, Camfield P, et al. Commission on outcome measurement in epilepsy, 1994-1997: final report. Epilepsia 1998;39:213312.
  • 10
    Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: GoldMR, RussellLB, SiegelJE, et al., eds. Cost-effectiveness in health and medicine. 1st ed. Oxford: Oxford University Press, 1996:176213.
  • 11
    Weisbrod BA. The valuation of human capital. J Polit Econ 1961;69:4236.
  • 12
    Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999;33:3955.
  • 13
    Heaney D, Sander JWAS. Ensuring appropriate care in epilepsy. Dis Manage Health Outcomes 1999;4:30313.
  • 14
    Koopmanschap MA, Rutten FFH, Van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:17189.
  • 15
    Johnson WG. The costs of epilepsy and cost-based evaluations of anticonvulsants. Pharmacoeconomics 1997;12:44659.
  • 16
    Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998;7:11925.
  • 17
    Navarro RP, Ashraf T. Cost analysis of carbamazepine, phenytoin, and valproate for use in complex partial seizures. Pharmacoeconomics 1993;March:1138.
  • 18
    Levy P. Pharmacoeconomic evaluation of medical treatment of epilepsy: where do we stand? Acta Neurol Belg 1999;99:23946.
  • 19
    Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996;5:8995.
  • 20
    Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999;8:813.
  • 21
    O'Neill BA, Trimble MR, Bloom DS. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure 1995;4:3744.
  • 22
    Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1998;51:102633.
  • 23
    Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998;53:4217.
  • 24
    Wiebe S, Gafni A, Blume WT, et al. An economic evaluation of surgery for temporal lobe epilepsy. J Epilepsy 1995;8:22735.
  • 25
    King JT, Sperling MR, Justice AC, et al. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg 1997;87:208.
  • 26
    Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia 1997;38:15463.
  • 27
    Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:37680.